Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial - Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Keedy, Vicki (Vanderbilt University Medical Center) ; Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ; Shepherd, Frances A. (University of Toronto) ; Insa, Amelia (Hospital Clínic Universitari (València)) ; Brown, Holly (Merck & Co., Inc., Whitehouse Station) ; Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ; Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ; Reilly, John F.. (Merck & Co., Inc., Whitehouse Station) ; Mauro, David (Merck & Co., Inc., Whitehouse Station) ; Hsu, Karl (Sanofi Aventis) ; Yan, Li (Merck & Co., Inc., Whitehouse Station) ; Universitat Autònoma de Barcelona